TBPH Q2 2017 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-35.9% YoY

Gross Profit

$2M61.1% margin

Operating Income

-$65M-1855.8% margin

Net Income

-$66M-1889.1% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+13.7%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$45M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$544M

Total Liabilities

$303M

Stockholders' Equity

$241M

Cash & Equivalents

$140M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-35.9%
Gross Profit	$2M	$5M	-55.6%
Operating Income	-$65M	-$47M	-37.1%
Net Income	-$66M	-$47M	-40.4%